The global impact of vaccination against hepatitis B: A historical overview

Vaccine

Volumn 26, Issue 49, 2008, Pages 6266-6273

  Zanetti, Alessandro R ^a   Van Damme, Pierre ^b   Shouval, Daniel ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Faculty of Medicine   (Belgium)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Hepatitis B; Strategies of immunisation; Vaccination

Indexed keywords

HEPATITIS B VACCINE;

ARTICLE; CANCER PREVENTION; CHRONIC LIVER DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HISTORY; HUMAN; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MUTATION; VACCINES, DNA;

EID: 55249103335     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.056     Document Type: Article

References (84)

1. Kidd-Ljunggren K., Miyakawa Y., and Kidd A.H. Genetic variability in hepatitis B viruses. J Gen Virol 83 (2002) 1267-1280
2. Norder H., Couroucé A.M., Coursaget P., Echevarria J.M., Lee S.D., Mushahwar I.K., et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47 (2004) 289-309
3. Shaefer S. Hepatitis B virus: significance of genotypes. J Viral Hep 12 (2005) 111-124
4. Erhardt A., Blondin D., Hauck K., Sagir A., Kohnle T., Heintges T., et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 54 (2005) 1009-1013
5. Kane M.A. Global status of hepatitis B immunisation. Lancet 348 (1996) 696
6. Lee W.M. Hepatitis B virus infection. N Engl Med 337 (1997) 1733-1745
7. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., and Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34 (2005) 1329-1339
8. World Health Organization. WHO expanded programme on immunisation. Global Advisory Group. Weekly Epidemiol Rec 3 (1992) 11-16
9. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Eng J Med 303 (1980) 833-841
10. Mast E., Mahoney F., Kane M., and Margolis H. Hepatitis B vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccine 2004 (2004), Saunders, Philadelphia 299-337
11. McAleer W.J., Buynack E.B., Maigetter R.Z., Wampler D.E., Miller W.J., and Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature 307 (1984) 178-180
12. Tong N.K., Beran J., Kee S.A., Miguel J.L., Sánchez C., Bayas J.M., et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 68 (2005) 2298-2303
13. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 8 (2008) 235-247
14. Zuckerman J.N., Zuckerman A.J., Symington I., Du W., Williams A., Dickson B., et al. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 34 (2001) 798-802
15. Rendi-Wagner P., Shouval D., Genton B., Lurie Y., Rumke H., Boland G., et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24 (2006) 2781-2789
16. Lo C.M., Lau G.K., Chan S.C., Fan S.T., and Wong J. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant 7 (2007) 434-439
17. Duclos P. Safety of immunization and adverse events following vaccination against hepatitis B. J Hepatol 39 (2003) S83-S88
18. Confavreux C., Suissa S., Saddier P., Bourdes V., and Vakusic S. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 344 (2001) 319-326
19. Ascherio A., Zhang S., Hernàn M., Olek M.J., Coplan P.M., Brodovicz K., et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344 (2001) 327-332
20. Naismith R.T., and Cross A.H. Does the hepatitis B vaccine cause multiple sclerosis?. Neurology 63 (2004) 772-773
21. Hernàn M.A., Jick S.S., Olek M.J., and Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. A prospective study. Neurology 63 (2004) 838-842
22. WHO. World Health Organization Global Advisory Committee on Vaccine Safety: Response to the paper by MA Hernán and others in Neurology 14th September 2004 issue entitled "Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis." Available at: http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/sep_04/en/index.html. Accessed February 26, 2008.
23. Jilg W., Schmidt M., Zachoval R., and Deinhardt F. Hepatitis B vaccination: how long does protection last?. Lancet 2 (1984) 458
24. Jilg W., Schmidt M., and Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 6 (1988) 201-207
25. West D.J., and Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14 (1996) 1019-1027
26. Banatvala J.E., and Van Damme P. Hepatitis B vaccine-do we need boosters?. J Hepatol 10 (2003) 1-6
27. European Consensus Group on Hepatitis B immunity. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 355 (2000) 561-565
28. Kao J.-H., and Chen D.S. Hepatitis B vaccination: to boost or not to boost?. Lancet 366 (2005) 1337-1338
29. Zanetti A.R., Mariano A., Romanò L., D'Amelio R., Chironna M., Coppola R.C., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 366 (2005) 1379-1384
30. Coleman P.F. Detecting hepatitis B surface antigen mutants. Emerg Infect Dis 12 (2006) 198-203
31. Zanetti A.R., Tanzi E., Manzillo G., Maio G., Sbreglia C., Caporaso N., et al. Hepatitis B variant in Europe. Lancet ii (1988) 1132-1133
32. Carman W.F., Zanetti A.R., Karayiannis P., Waters J., Manzillo G., Tanzi E., et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336 (1990) 325-329
33. Ogata N., Zanetti A.R., Yu M., Miller R.H., and Purcell R.H. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. J Infect Dis 175 (1997) 511-523
34. Hsu H.-Y., Chang M.-H., Ni Y.-H., Lin H.-H., Wang S.-M., and Chen D.-S. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 26 (1997) 786-791
35. Carman W.F., Thomas H.C., Zuckerman A.J., and Harrison T.J. Molecular variants of hepatitis B virus. In: Zuckerman A.J., and Thomas H.C. (Eds). Viral hepatitis. 2nd ed. (1998), Churchill Livingstone, London 141-172
36. Zuckerman A.J. Effect of hepatitis B virus mutants on efficacy of vaccination. Lancet 355 (2000) 1382-1384
37. Francois G., Kew M., Van Damme P., Mphahlele M.J., and Meheus A. Mutant hepatitis B virus: a matter of academic interest only or a problem with far-reaching implications?. Vaccine 19 (2001) 3799-3815
38. Hsu H.-Y., Chang M.-H., Ni Y.-H., and Chen H.-L. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 53 (2004) 1499-1503
39. Ogata N., Cote P.J., Zanetti A.R., Miller R.H., Shapiro M., Gerin J., et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 30 (1999) 779-786
40. Cariani E., Ravaggi A., Tanzi E., Romanò L., Fiordalisi G., Bellati G., et al. Emergence of hepatitis B virus S gene mutant in a liver transplant patient. J Med Virol 47 (1995) 410-415
41. Mele A., Tancredi F., Romanò L., Giuseppone A., Colucci M., Sangiuolo A., et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis 184 (2001) 905-908
42. van Houdt R., Sonder G.J., Dukers N.H., Bovee L.P., van den Hoek A., Coutinho R.A., et al. Impact of targeted hepatitis B vaccination program in Amsterdam, the Netherlands. Vaccine 25 (2007) 2698-2705
43. Kretzschmar M., and de Wit A. Universal hepatitis B vaccination. Lancet 8 (2008) 85-87
44. Banatvala J., Van Damme P., and Emiroglu N. Hepatitis B immunization in Britain: time to change?. BMJ 332 (2006) 804-805
45. Pollard A.J. Hepatitis B vaccination. BMJ 335 (2007) 950
46. Zuckerman J.N., and van Hattum J. Universal hepatitis B vaccination. Lancet 8 (2008) 90
47. Grosheide P., and Van Damme P. Prevention and control of hepatitis B in the community. In: Hallauer J., Kane M., McCloy E., Meheus A., and Roure C. (Eds). Communicable diseases series 1 (1996), Viral Hepatitis Prevention Board, University of Antwerp, Antwerpen
48. Francois G., Hallauer J., and Van Damme P. Hepatitis B vaccination: how to reach risk groups. Vaccine 21 (2002) 1-4
49. Van Damme P., Kane M., and Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. BMJ 314 (1997) 1033-1037
50. World Health Organization. Expanded Programme on Immunization. Global Advisory Group. Weekly Epidemiol Rec 3 (1992) 11-16
51. World Health Organization. Hepatitis B vaccines. WHO position paper. Weekly Epidemiol Rec 28 (2004) 255-263
52. World Health Organization (2006). Vaccines and Biologicals. WHO vaccine preventable disease monitoring system. Global summary 2006 (data up to 2006). Available at: http://www.who.int/immunization_monitoring/diseases/hepatitis/en/ (accessed on 26 February 2008).
53. Tilson L., Thornton L., O'Flanagan D., Johnson H., and Barry M. Cost-effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health (2008) 1-8
54. Van Damme P., Van Herck K., Leuridan E., and Vorsters A. Introducing universal hepatitis B vaccination in Europe: differences still remain between countries. Eurosurveill Weekly 9 (2004) 67-68
55. Shepard C.W., Simard E.P., Finelli L., Fiore E., and Bell B.P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28 (2006) 112-125
56. World Health Organization. Statistics on hepatitis B. Available at: http://www.who.int/immunization_monitoring/diseases/HepB_coverage.jpg (accessed on 29 February 2008).
57. Coursaget P., Leboulleux D., Soumare M., le Cann P., Yvonnet B., Chiron J.P., et al. Twelve-year follow-up study of hepatitis B immunisation of Senegalese infants. J Hepatol 21 (1994) 250-254
58. EUROHEP.NET. Data on surveillance and prevention of hepatitis A and B in 22 countries, 1990-2001. Antwerp: EUROHEP.NET; 2004 (also available on www.eurohep.net).
59. Chan C.Y., Lee S.D., and Lo K.J. Legend of hepatitis B vaccination: the Taiwanese experience. J Gastroenterol Hepatol 19 (2004) 121-126
60. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Hsu H.M., Wu T.C., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336 (1997) 1855-1859
61. Whittle H.C., Maine N., Pilkington J., Mendy M., Fortuin M., Bunn J., et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 345 (1995) 1089-1092
62. Viviani S., Jack A., Hall A.J., Maine N., Mendy M., Montesano R., et al. Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age. Vaccine 17 (1999) 2946-2950
63. Ng K.P., Saw T.L., Baki A., Rozainah K., Pang K.W., and Ramanathan M. Impact of expanded programme on immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol 194 (2005) 163-168
64. Perz J.F., Elm Jr. J.L., Fiore A.E., Huggler J.I., Kuhnert W.L., and Effler P.V. Near elimination of hepatitis B infections among Hawaii elementary school children universal infant hepatitis B vaccination. Pediatrics 118 (2006) 1403-1408
65. Wainwright R., Bulkow L.R., Parkinson A.J., Zanis C., and McMahon B.J. Protection provided by hepatitis B vaccine in a Yupik Eskimo Population: results of a 10 year study. J Infect Dis 175 (1997) 674-677
66. Piazza M., Da Villa G., Picciotto L., Abrescia N., Guadagnino V., Memoli A.M., et al. Mass vaccination against hepatitis B in infants in Italy. Lancet 332 (1988) 1132
67. Zanetti A.R., Tanzi E., Romanò L., and Grappasonni I. Vaccination against hepatitis B: the Italian strategy. Vaccine 11 (1993) 521-524
68. Romanò L., Mele A., Pariani E., Zappa A., and Zanetti A. Update in the universal vaccination against hepatitis B in Italy: 12 years after its implementation. Eur J Public Health 14 suppl (2004) S19
69. Bonanni P., Pesavento G., Bechini A., Tiscione E., Mannelli F., Benucci C., et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 21 (2003) 685-691
70. Da Villa G., Romanò L., Sepe A., Iorio R., Parimbello N., Zappa A., et al. Impact of hepatitis B vaccination in high endemic area of south Italy and long-term duration of anti-HBs antibody in two cohort of vaccinated individuals. Vaccine 25 (2007) 3133-3136
71. Gaeta G.B., Stroffolini T., Chiaramonte M., Ascione T., Stornaiuolo G., Lobello S., et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 32 (2000) 824-827
72. Shouval D. Hepatitis B vaccines. J Hepatol 39 (2003) S70-S76
73. Milich D.R., Thornton G.B., Neurath A.R., Kent S.B., Michel M.L., Tiollais P., et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228 (1985) 1195-1199
74. 2 antigens. Vaccine 9 (1991) 545-548
75. Shouval D., Ilan Y., Adler R., Deepen R., Panet A., Even-Chen Z., et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 12 (1994) 1453-1459
76. Wagner D., Wagenbreth I., Stachan-Kunstyr R., Thoma H.A., Hemmerling A.E., and Flik J. Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1 and pre-S2 and S gene products. Clin Invest 72 (1994) 350-352
77. Wilson J.N., Nokes D.J., Medley G.F., and Shouval D. Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules. Vaccine 25 (2007) 3705-3712
78. Shapira M.Y., Zeira E., Adler R., and Shouval D. Rapid seroprotection against hepatitis B following the first dose of Pre-S1/Pre-S2/S vaccine. J Hepatol 34 (2001) 123-127
79. Podda A., and Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with optimal safety profile. Expert Rev Vaccines 2 (2003) 197-203
80. Cooper C.L., Davis H.L., Angel J.B., Morris M.L., Elfer S.M., Seguin I., et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected patients. AIDS 19 (2005) 1473-1479
81. Bienzle U., Guenther M., Neuhaus R., Vandepapeliere P., Vollmar J., Lun A., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B related disease. Hepatology 38 (2003) 811-819
82. Sprengers D., and Janssen H.L.A. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 19 (2004) 17-26
83. Shouval D., and Ilan Y. Immunization against hepatitis B through adoptive transfer of immunity. Intervirology 38 (1995) 41-46
84. Mancini-Ourgine M., Fontaine H., Brechot C., Pol S., and Michel M.L. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24 (2006) 4482-4489